Hashemi Mohammad, Bahari Gholamreza, Markowski Jarosław, Małecki Andrzej, Łos Marek J, Ghavami Saeid
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Oncotarget. 2018 May 15;9(37):24857-24868. doi: 10.18632/oncotarget.25324.
This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96, = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67-0.86, < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.
本研究旨在评估程序性细胞死亡蛋白6（PDCD6）基因多态性与癌症易感性之间的关系。检索在线数据库，查找截至2017年11月发表的相关病例对照研究。使用Review Manage（RevMan）5.3进行统计分析。采用合并比值比（OR）及其95%置信区间（CI）来计算关联强度。总体而言，我们的结果表明，在共显性（OR = 0.82，95%CI = 0.70 - 0.96，P = 0.01，TG与TT相比；OR = 0.53，95%CI = 0.39 - 0.72，P < 0.0001，GG与TT相比）、显性（OR = 0.76，95%CI = 0.66 - 0.89，P = 0.0004，TG + GG与TT相比）、隐性（OR = 0.57，95%CI = 0.43 - 0.78，P = 0.0003，GG与TT + TG相比）和等位基因（OR = 0.76，95%CI = 0.67 - 0.86，P < 0.00001，G与T相比）遗传模型下，PDCD6 rs3756712 T>G多态性与癌症风险降低显著相关。该发现不支持PDCD6的rs4957014 T>G多态性与不同癌症风险之间存在关联。
Zotero 插件
